Ann W Olmsted

age ~67

from Palo Alto, CA

Get Report

Also known as:

Ann Walls Olmsted
Anna W Olmsted
Ann W Olmstead

Phone and address:: 3759 La Donna Ave, Palo Alto, CA 94306
(650)4936908

Connected to:

Ann Olmsted Phones & Addresses

3759 La Donna Ave, Palo Alto, CA 94306 • (650)4936908
Los Angeles, CA
1001 Harvey Rd, College Station, TX 77840 • (979)6935665
3759 La Donna Ave, Palo Alto, CA 94306 • (510)7173136

Work

Company:

Theravance biopharma us, inc.
Dec 2016
Position:

Statistical consultant

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

Texas A&M University
1995 to 1999
Specialities:

Statistics, Philosophy

Skills

Biostatistics

Emails

o***[email protected]

Industries

Pharmaceuticals

Resumes

Statistical Consultant

view source

Location:

199 east Blaine St, Seattle, WA 98109

Industry:

Pharmaceuticals

Work:

Theravance Biopharma Us, Inc.
Statistical Consultant
Gilead Sciences Jan 2013 - Sep 2016
Associate Director, Biostatistics at Gilead Sciences
Gilead Sciences Jun 2009 - Jan 2013
Senior Manager, Biostatistics
Cv Therapeutics Aug 2002 - Jun 2009
Associate Director, Biostatistics
Cv Therapeutics Dec 2001 - Aug 2002
Senior Manager, Biostatistics

Education:

Texas A&M University 1995 - 1999
Doctorates, Doctor of Philosophy, Statistics, Philosophy Cal State East Bay - College of Business & Economics
Master of Science, Masters, Statistics

Skills:

Biostatistics

Us Patents

Use Of Aadenosine Receptor Agonists
view source
US Patent:

8106029, Jan 31, 2012
Filed:

Dec 14, 2009
Appl. No.:

12/637583
Inventors:

Toufigh Gordi - Sunnyvale CA, US
Ann Walls Olmsted - Palo Alto CA, US
Hsiao Dee Lieu - Burlingame CA, US
Luiz Belardinelli - Palo Alto CA, US
Assignee:

Gilead Sciences, Inc. - Foster City CA
International Classification:

A61K 31/70
C07H 19/167
US Classification:

514 46, 536 2761
Abstract:

Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine Areceptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.

Use Of A2A Adenosine Receptor Agonists
view source
US Patent:

20060084625, Apr 20, 2006
Filed:

Oct 19, 2005
Appl. No.:

11/253322
Inventors:

Toufigh Gordi - Sunnyvale CA, US
Ann Olmsted - Palo Alto CA, US
Hsiao Lieu - Burlingame CA, US
Luiz Belardinelli - Palo Alto CA, US
International Classification:

A61K 31/7076
US Classification:

514046000
Abstract:

Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine Areceptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.

Use Of A2A Adenosine Receptor Agonists
view source
US Patent:

20120189538, Jul 26, 2012
Filed:

Dec 21, 2011
Appl. No.:

13/333789
Inventors:

Toufigh Gordi - Sunnyvale CA, US
Ann Walls Olmsted - Palo Alto CA, US
Hsiao Dee Lieu - Burlingame CA, US
Luiz Belardinelli - Palo Alto CA, US
International Classification:

A61K 31/7076
A61K 51/00
A61P 9/08
US Classification:

424 111, 514 46
Abstract:

Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine Areceptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.